Relay Therapeutics Inc Dossier
Outlook & Key Dates
Estimates, guidance, catalysts, and upcoming events
Analyst Estimates Learn more →
5-Yr Fwd EPS Growth
0.1%projected annual EPS growth
Analyst Coverage
13analysts covering
FY EPS (est.)
-$1.64next fiscal year
Reporting Calendar
| Event | Expected Date |
|---|---|
| Q3 2026 Earnings Release | 5 Nov 2026 |
Monitoring Framework
Key Performance Indicators
Cash, Cash Equivalents, and Investments Quarterly642.1MTarget: Sufficient to fund operations into 2029
Zovegalisib Median Progression-Free Survival (PFS) in CDK4/6-Experienced Patients Annually11.1Target: Demonstrate superior efficacy over standard of care in Phase 3 ReDiscover-2
Zovegalisib Volumetric Response Rate in PIK3CA-Driven Vascular Anomalies Annually6,000.0%Target: Maintain high response rate and chronic tolerability in expanded cohorts
Watch Items
- Phase 3 ReDiscover-2 Trial ProgressTrigger: Enrollment completion or interim efficacy readoutsAction: Evaluate clinical timeline and adjust commercialization readiness plans
- Frontline Breast Cancer Triplet Phase 3 InitiationTrigger: Trial initiation in early 2027Action: Monitor R&D expenditure ramp and clinical supply execution with Pfizer
- Cash Burn Rate and RunwayTrigger: Quarterly net cash outflows exceeding $80 millionAction: Assess capital allocation, ATM utilization, and potential out-licensing opportunities
Research as of 20 Jun 2026